Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 5/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SOD1 | P00441 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631599 | 0.93 | QPCT (0.50) | QPCTGSK3AGSK3BSMN1; SMN2KDM4E | |
| SCHEMBL3632199 | 0.88 | QPCT (0.57) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL3629352 | 0.87 | GSK3A (0.64) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL3629884 | 0.87 | NAMPT (0.56) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL3631942 | 0.86 | QPCT (0.52) | QPCTSMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL3632114 | 0.84 | GSK3A (0.60) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL3629432 | 0.84 | GSK3A (0.60) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL3633442 | 0.83 | GSK3A (0.57) | GSK3AGSK3BNAMPTSMN1; SMN2KDM4E | |
| SCHEMBL3627882 | 0.83 | QPCT (0.56) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL3632003 | 0.82 | SMN1; SMN2 (0.64) | QPCTGSK3AGSK3BNAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142536-B1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-10-21 | — | — | EP | claimed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | claimed |
| EP-2142536-B1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188094-B2 | Imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 1-(3,4-dimethoxyphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thiourea | PROBIODRUG AG (DE) | 2012-05-29 | — | — | US | disclosed |
| EP-2142536-A1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008128984-A1 | AMINOPYRIMIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260688-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885GSK3A 754/4885GSK3B 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.